Cristofoletti Rodrigo, Charoo Naseem A, Dressman Jennifer B
Brazilian Health Surveillance Agency (ANVISA), Division of Therapeutic Equivalence, Brasilia, Brazil; Institute of Pharmaceutical Technology, Goethe University, Frankfurt am Main, Germany.
AlFalah Life Sciences Pvt. Ltd., Wathora, Budgam, India; Emirates Pharma, Alrigga, Deira, Dubai, United Arab Emirates.
J Pharm Sci. 2016 Sep;105(9):2794-2803. doi: 10.1016/j.xphs.2016.01.027. Epub 2016 Mar 15.
Due to the higher total clearance of certain drugs in children than in adults, it is recommended that, in such cases, higher relative doses on a milligram/kilogram basis should be administered to children in order to achieve similar systemic exposure to adults. This is the case for fluconazole and ketoconazole. Even though the lower absorptive surface area and smaller volumes of intestinal fluids in children does not affect fluconazole absorption, cumulative fraction absorbed of ketoconazole seems to be dose dependent. A dose of 200 mg of ketoconazole, which belongs to the class 2a of the Developability Classification System (DCS) in adults, seems to be higher than the maximum absorbable dose in children, and ketoconazole absorption is expected to be solubility limited (i.e., DCS class 2b) in this population, indicating a DCS class migration. Therefore, extrapolating DCS and DCS drug classification from adults to pediatric groups does not seem to be straightforward and the development of specific pediatric classification systems should be a high priority.
由于某些药物在儿童体内的总清除率高于成人,因此建议在这种情况下,应以毫克/千克为基础给予儿童更高的相对剂量,以实现与成人相似的全身暴露。氟康唑和酮康唑就是这种情况。尽管儿童较低的吸收表面积和较少的肠液体积不影响氟康唑的吸收,但酮康唑的累积吸收分数似乎与剂量有关。酮康唑200毫克的剂量在成人中属于可开发性分类系统(DCS)的2a类,在儿童中似乎高于最大可吸收剂量,预计酮康唑在该人群中的吸收受溶解度限制(即DCS 2b类),这表明DCS类别发生了迁移。因此,将DCS和DCS药物分类从成人外推到儿科群体似乎并非易事,开发特定的儿科分类系统应成为高度优先事项。